Clinical Trials

33 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04628767 2026-04-14

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Phase 2/3 Recruiting

249 enrolled

Renal Pelvis and Ureter Urothelial Carcinoma

NCT03220022 2026-04-13

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

46 enrolled 19 charts

Lymphoma, AIDS-Related

NCT03609216 2026-04-13

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

237 enrolled

Phase 3 Active not recruiting

Infiltrating Bladder Urothelial Carcinoma

NCT03907488 2026-04-13

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

994 enrolled 11 charts 2 FDA

Hodgkin Disease

NCT07525869 2026-04-13

An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy

Phase NA Recruiting

40 enrolled

Triple Negative Breast Neoplasms

NCT06738368 2026-04-08

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

30 enrolled

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04685616 2026-03-30

RADAR

Phase 3 Recruiting

1,042 enrolled

Hodgkin Disease

NCT00066443 2026-03-27

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Phase 1/2 Completed

93 enrolled

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT06528691 2026-03-23

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

Phase 2 Not yet recruiting

52 enrolled

CNS

Glioma, Central Nervous System Neoplasms

NCT07021989 2026-03-17

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

38 enrolled

Other hematologic neoplasm

Hodgkin Disease

NCT03214562 2026-03-05

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Recruiting

116 enrolled

Leukemia, Myeloid, Acute

NCT04684368 2026-02-24

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

160 enrolled

Choriocarcinoma, Teratoma, Carcinoma, Embryonal

NCT05296317 2026-02-19

EMEG-ECDD

Phase NA Completed

97 enrolled

Breast Neoplasms

NCT06709495 2026-02-19

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Phase 1/2 Recruiting

63 enrolled

Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Desmoplastic Small Round Cell Tumor

NCT03136146 2026-02-17

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

42 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03147612 2026-02-17

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

22 enrolled

Blast Crisis, Leukemia, Myeloid, Accelerated Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03301350 2026-02-13

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

29 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05535166 2026-02-12

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

130 enrolled

CNS

Brain Neoplasms, Medulloblastoma

NCT05753618 2026-02-09

REaCT-OGF

Phase 4 Recruiting

242 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06594939 2026-02-04

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

31 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04323956 2026-02-02

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

50 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03943901 2026-01-29

Split-Dose R-CHOP for Older Adults With DLBCL

27 enrolled 11 charts

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT04294641 2026-01-23

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

Other hematologic neoplasm

10 enrolled 15 charts

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT06220032 2026-01-05

HO170DLBCL

Phase 3 Recruiting

324 enrolled

LymphoidSarcoma

Heart Failure, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating, Cardiotoxicity

NCT06690775 2025-12-23

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

230 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT01850888 2025-12-18

MIBG for Refractory Neuroblastoma and Pheochromocytoma

Phase NA Completed

15 enrolled

CNSEndocrine

Neuroblastoma, Pheochromocytoma

NCT01871766 2025-12-17

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Phase 1 Not yet recruiting

115 enrolled

Sarcoma

Rhabdomyosarcoma

NCT07278856 2025-12-12

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

20 enrolled

Phase 2/3 Active not recruiting

Lymphoma, T-Cell

NCT01046825 2025-12-10

Mature B-Cell Lymphoma And Leukemia Study III

128 enrolled 12 charts

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin

NCT01840566 2025-12-03

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

17 enrolled

Lymphoma, Non-Hodgkin, Recurrence

NCT07188090 2025-11-28

HSCT

100 enrolled

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT03571633 2025-11-26

BREASTIMMU02

90 enrolled

Phase 3 Active not recruiting

HER2-positive Breast Cancer

NCT01933932 2025-11-19

SELECT-1

510 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02369458 2025-11-18

Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies

48 enrolled 12 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03036488 2025-10-29

MK-3475-522

Phase 3 Completed

1,174 enrolled 2 FDA

Triple Negative Breast Neoplasms

NCT02909036 2025-10-10

Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.

46 enrolled

Plasma cell

Amyloidosis, Multiple Myeloma

NCT05645718 2025-10-07

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Other hematologic neoplasm

27 enrolled

Leukemia

NCT05870748 2025-09-23

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Phase 2/3 Terminated

600 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04383743 2025-09-18

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

17 enrolled 12 charts

Urinary Bladder Neoplasms

NCT03107988 2025-09-15

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Phase 1 Completed

65 enrolled 38 charts

CNS

Neuroblastoma

NCT00911183 2025-08-29

FRAIL-06

67 enrolled 11 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT03646123 2025-08-28

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Phase 2 Terminated

255 enrolled 29 charts

Hodgkin Disease

NCT06616987 2025-08-28

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

40 enrolled

Phase 1/2 Active not recruiting

Breast Cancer Metastatic

NCT05011188 2025-08-27

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

44 enrolled

Prostatic Neoplasms

NCT00334815 2025-08-24

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

29 enrolled 10 charts

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

NCT06023641 2025-08-19

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

135 enrolled

Sarcoma

Rhabdomyosarcoma

NCT05032183 2025-08-11

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 1/2 Terminated

4 enrolled 8 charts

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00049595 2025-08-05

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma

Phase 3 Completed

552 enrolled

Phase 3 Active not recruiting

Hodgkin Disease, Lymphoma

NCT00070564 2025-07-31

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

3,294 enrolled 22 charts